This facility has not been out of compliance in the past 12 quarters. View detailed information from the Environmental Protection Agency. Note: There are no mandated limits for power plant ...

Shares of Kezar Life Sciences (NASDAQ:KZR) fell 11% Thursday after the company said its board of directors had unanimously rejected an unsolicited takeover offer from Concentra Biosciences and ...

Sept 30 (Reuters) - Kezar Life Sciences (KZR.O), opens new tab ... bank earnings; Tesla falls 1:09 PM UTC · Updated ago category Sanofi in talks to sell 50% stake in consumer health business ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

With Kezar Life Sciences’ lupus plans up in the air while the company investigates patient deaths, Concentra Biosciences has spied an opportunity to scoop up another troubled biotech.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Oct 17 (Reuters) - Kezar Life Sciences (KZR.O), opens new tab said on Thursday it would terminate its mid-stage trial studying its experimental drug in patients with active lupus nephritis and ...

(RTTNews) - Kezar Life Sciences (KZR) announced that its Board has rejected the unsolicited, non-binding proposal from Concentra Biosciences, to acquire all of the outstanding shares of common ...

Kezar Life Sciences Inc, based in the USA, is a clinical-stage biotechnology company focused on developing small molecule therapeutics for autoimmunity and cancer. Its product pipeline includes ...

SOUTH SAN FRANCISCO, Calif., October 10, 2024--(BUSINESS WIRE)--Kezar Life Sciences, Inc. ("Kezar" or the "Company") (Nasdaq: KZR), a clinical-stage biotechnology ...